Table 3.
Results of conditional logistic regression analysis of the dose–response relationship between current use of Beclomethasone and use of antidiabetics (n = 15 187).
| Rate ratio | 95% confidence interval | |
|---|---|---|
| Crude model | ||
| IC* use | ||
| Non-user | 1.0 | |
| Beclomethasone-Dose I | 1.1 | 0.9, 1.3 |
| Beclomethasone-Dose II | 1.6 | 1.4, 1.9 |
| Adjusted model | ||
| IC use | ||
| Non-user | 1.0 | – |
| Beclomethasone-Dose I | 0.8 | 0.7, 1.0 |
| Beclomethasone-Dose II | 1.4 | 0.9, 1.2 |
| Oral corticosteroids | ||
| No | 1.0 | – |
| Yes | 2.7 | 2.3, 3.2 |
| Age (years) | ||
| 65–74.9 | 1.0 | – |
| 75–84.9 | 0.8 | 0.7, 0.9 |
| >85 | 0.7 | 0.5, 0.9 |
| Gender | ||
| Male | 1.0 | – |
| Female | 1.3 | 1.1,1.5 |
| Number of concurrent prescriptions | ||
| 0 | 1.0 | – |
| >1 | 2.2 | 1.9, 2.5 |
| Physician visits | ||
| 0–24 | 1.0 | – |
| 25–48 | 1.2 | 1.0, 1.5 |
| >48 | 1.4 | 1.2, 1.8 |
| Hospitalizations | ||
| 0 | 1.0 | – |
| 1–3 | 1.2 | 1.0, 1.6 |
| >3 | 1.6 | 1.2, 2.0 |
*
Inhaled corticosteroid. Beclomethasone dose I refers to low dose (50 µg/puff, while dose II refers to high dose (250 µg/puff).